Terms: = Prostate cancer AND TPM3, ENSG00000143549, 7170
12 results:
1. A prospective study of the prostate health index density and multiparametric magnetic resonance imaging in diagnosing clinically significant prostate cancer.
Chen Y; Xu D; Ruan M; Li H; Lin G; Song G
Investig Clin Urol; 2023 Jul; 64(4):363-372. PubMed ID: 37417561
[TBL] [Abstract] [Full Text] [Related]
2. Small molecules targeting the disordered transactivation domain of the androgen receptor induce the formation of collapsed helical states.
Zhu J; Salvatella X; Robustelli P
Nat Commun; 2022 Oct; 13(1):6390. PubMed ID: 36302916
[TBL] [Abstract] [Full Text] [Related]
3. Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements.
Tsai JW; Lee JC; Hsieh TH; Huang SC; Lee PH; Liu TT; Kao YC; Chang CD; Weng TF; Li CF; Lin JC; Liang CW; Su YL; Chang IY; Wang YT; Chang NY; Yu SC; Wang JC; Huang HY
Mod Pathol; 2022 Jul; 35(7):911-921. PubMed ID: 35149769
[TBL] [Abstract] [Full Text] [Related]
4. Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor-positive prostate and Breast cancers.
Tien AH; Sadar MD
Mol Cancer Ther; 2022 Feb; 21(2):294-309. PubMed ID: 34815359
[TBL] [Abstract] [Full Text] [Related]
5. Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes.
Acosta AM; Sholl LM; Dickson BC; McKenney JK; Gordetsky JB; Pins MR; Marino-Enriquez A; Dong F; Dubuc AM; Cin PD; Fletcher CDM
Mod Pathol; 2021 Sep; 34(9):1763-1779. PubMed ID: 33986460
[TBL] [Abstract] [Full Text] [Related]
6. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract] [Full Text] [Related]
7. A New Nomogram Allowing Physicians to Predict Patients at High Risk of Fever Occurring After prostate Biopsy.
Xia H; Wang H; Chen L; Meng J; Zhou J; Liang C
Med Sci Monit; 2020 Mar; 26():e921350. PubMed ID: 32200388
[TBL] [Abstract] [Full Text] [Related]
8. Development and validation of prognostic nomograms for patients with metastatic prostate cancer.
Jiang WD; Yuan PC
Int Urol Nephrol; 2019 Oct; 51(10):1743-1753. PubMed ID: 31289983
[TBL] [Abstract] [Full Text] [Related]
9. Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer.
Zhang Y; Zeng N; Zhu YC; Huang YXR; Guo Q; Tian Y
World J Surg Oncol; 2018 Jun; 16(1):102. PubMed ID: 29859119
[TBL] [Abstract] [Full Text] [Related]
10. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade prostate cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for prostate cancer.
Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H
Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895
[TBL] [Abstract] [Full Text] [Related]
11. Significant association of catechol-O-methyltransferase Val158Met polymorphism with bladder cancer instead of prostate and kidney cancer.
Chen Y; Yu X; Li T; Yan H; Mo Z
Int J Biol Markers; 2016 May; 31(2):e110-7. PubMed ID: 27055785
[TBL] [Abstract] [Full Text] [Related]
12. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
[TBL] [Abstract] [Full Text] [Related]
